Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

nued and hydration for several days is recommended.
Please see accompanying full Prescribing Information in the Package Insert or on the Ganite
website at www.ganite.com.

About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is
focused on delivering innovative products for the treatment of patients with cancer. The
Company’s research platform is anchored by two major programs that center on oligonucleotides
(RNA- and DNA- based medicines) and small molecules. Genasense® (oblimersen sodium)
Injection is the Company's lead compound from its oligonucleotide program. The leading drug
in Genta’s small molecule program is Ganite® (gallium nitrate injection), which the Company is
exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related
hypercalcemia that is resistant to hydration. Genta is partnered with IDIS
(www.idispharma.com) on a program whereby both Ganite® and Genasense® are available on a
“named-patient” basis in countries outside the United States. For more information about Genta,
please visit our website at: www.genta.com.

Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on circumstances that will occur in the
future. Forward-looking statements include, without limitation, statements about:
• the Company’s ability to obtain necessary regulatory approval for Genasense® from the
U.S. Food and Drug Administration (“F
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Oct. 16 AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) ... molecules that are potent inhibitors of the Id ... filing of this patent,constitute major milestones in the ... Dr. Richard Salvador, President and CEO, and the,former ...
... Oct. 16 When eighty-six-year-old,Keith Hora went to see ... University of Newcastle in Australia, he was told he ... been diagnosed with stage III melanoma, one,of the most ... had multiple melanoma reoccurrences in the previously treated,area of ...
Cached Medicine Technology:AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... of Medicine at the University of Pennsylvania in collaboration ... $8 million grant from the National Cancer Institute (NCI) ... in patients with malignant pleural mesothelioma, a rare, aggressive ... the lining of the lungs and is caused almost ... a clinical trial and additional studies looking at the ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... groundbreaking program,dealing with the deteriorating physical, mental and ... gender specific psychological and,medical needs will take place ... under the auspices of members of the Westchester,medical ... J. Legato,M.D. and Lionel Tiger, Ph.D., Dr. ...
... Experts develop sequence of instructions they say could help doctors ... safety experts say that almost all kids who are allergic ... set of standard precautions. , Reporting in the September ... by the Johns Hopkins Children,s Center put forth a step-by-step ...
... Martin Schiff, M.D.,is an illustrious member and recognized authority ... career is detailed in "Who,s Who in,California," "Who,s Who ... in,the World," "Who,s Who in Medicine and Health Care" ... to devote his expertise to exposing the,inaccurate, misleading theories ...
... Coast states are open, CVS/pharmacy will also donate water, ice, diapers and ... communities impacted by Hurricane Gustav, ... in Louisiana have re-opened since Hurricane Gustav,in the following cities and towns:, ... City Broussard Covington Cutoff Destrehan Franklinton ...
... 4 In some countries, lime juice is,thought to ... Against such a backdrop of misinformation and stigma, ... killed tens of millions,of people?, Part of the ... news media, says,Internews Network, an international media development nonprofit ...
... SAFC Pharma(TM), a focus,area within SAFC(R) ( ... SIAL ), today officially announced details,of a ... facility,designed to significantly increase its capacity to produce ... investment,includes the purchase of 15 acres of green ...
Cached Medicine News:Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:CVS/pharmacy Re-Opens 64 Stores in Louisiana 2Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 3
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: